Back to top
more

VERADIGM INC (MDRX)

(Delayed Data from OTC)

$7.55 USD

7.55
226,006

-0.22 (-2.83%)

Updated May 24, 2024 03:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 249)

Industry: Technology Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights: MDRX, VEEV, DGX, TMO and ZM

by Zacks Equity Research

The Zacks Analyst Blog Highlights: MDRX, VEEV, DGX, TMO and ZM

Urmimala Biswas headshot

Is Another Great Depression Imminent or Is it Just a Myth?

by Urmimala Biswas

Asian countries have already shown clear signs of major economic recession.

Veeva Vault Picked by AstraZeneca for Quality Management

by Zacks Equity Research

The partnership with AstraZeneca will facilitate end-to-end quality management for Veeva (VEEVA).

The Zacks Analyst Blog Highlights: 10x Genomics, Allscripts Healthcare and NextGen Healthcare

by Zacks Equity Research

The Zacks Analyst Blog Highlights: 10x Genomics, Allscripts Healthcare and NextGen Healthcare

Here's Why You Should Retain Allscripts (MDRX) Stock for Now

by Zacks Equity Research

Investor confidence is high on Allscripts (MDRX) stock, thanks to solid prospects.

Urmimala Biswas headshot

3 Med Info Stocks to Improve Portfolio Health Amid Coronavirus Woes

by Urmimala Biswas

Postponement of elective surgeries leading to lower product bookings cloud Zacks-Medical Info Systems industry prospects. However, coronavirus-led demand for contactless services should aid the space. TXG, MDRX, NXGN should be the forerunners.

Sriparna Ghosal headshot

3 Remote Patient Monitoring Stocks in Focus Amid Coronavirus

by Sriparna Ghosal

In the wake of the pandemic, the remote patient monitoring space continues to thrive on a number of positive developments.

AllScripts (MDRX) Up 18.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

AllScripts (MDRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Allscripts Enhances Healthcare Innovation With Patent Program

by Zacks Equity Research

Allscripts (MDRX) continues to advance healthcare innovation by earning five new application patents.

Allscripts' Collaboration to Advance Healthcare Innovation

by Zacks Equity Research

Allscripts (MDRX) partners with Israel's Sheba Medical Center to help enhance healthcare innovation with smarter technology, thereby improving patient outcomes.

Allscripts (MDRX) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Allscripts (MDRX) witnessed decline in core Client Services and Software delivery unit revenues during Q2.

AllScripts Healthcare (MDRX) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

AllScripts (MDRX) delivered earnings and revenue surprises of 50.00% and 1.60%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for July 29th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

Analysts Estimate AllScripts Healthcare (MDRX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

AllScripts (MDRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Allscripts Extends Strategic Partnership With Microsoft

by Zacks Equity Research

Allscripts (MDRX) extends partnership with Microsoft that can help transform healthcare with smarter technology, thereby improving patient outcomes.

    Here's Why You Should Retain Allscripts (MDRX) Stock for Now

    by Zacks Equity Research

    Allscripts (MDRX) continues to benefit from lucrative deals and strong prospects in Sunrise EHR. However, margin contraction remains a woe.

    Trina Mukherjee headshot

    Remote Patient Monitoring Gains Prominence: 3 Stocks to Watch

    by Trina Mukherjee

    Let's keep a watch on three stocks that are committed toward enhancing and offering RPM to fight against coronavirus.

    Allscripts' (MDRX) Veradigm Partners with PAN Foundation

    by Zacks Equity Research

    This partnership between Allscripts (MDRX) and PAN Foundation is expected to boost patient outcomes.

    Sriparna Ghosal headshot

    3 Digital HealthCare Stocks in the Spotlight Amid Coronavirus

    by Sriparna Ghosal

    In the face of the pandemic, the digital health management space continues to thrive on a number of positive developments.

    Allscripts (MDRX) Looks Good: Stock Adds 9.1% in Session

    by Zacks Equity Research

    Allscripts (MDRX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

    AllScripts (MDRX) Up 18% Since Last Earnings Report: Can It Continue?

    by Zacks Equity Research

    AllScripts (MDRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Allscripts Unit Inks Deal to Boost Veradigm AccelRx Platform

    by Zacks Equity Research

    This deal is expected to bolster Allscripts' (MDRX) Clinical and Financial Solutions segment.

      Allscripts (MDRX) Q1 Earnings and Revenues Miss Estimates

      by Zacks Equity Research

      Allscripts (MDRX) witnessed a decline in core Client Services and Software delivery unit revenues in Q1.

      AllScripts Healthcare (MDRX) Q1 Earnings and Revenues Miss Estimates

      by Zacks Equity Research

      AllScripts (MDRX) delivered earnings and revenue surprises of -35.71% and -1.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

      Analysts Estimate AllScripts Healthcare (MDRX) to Report a Decline in Earnings: What to Look Out for

      by Zacks Equity Research

      AllScripts (MDRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.